No evidence that hangover cures work

December 22, 2005

No compelling evidence exists to suggest that any complementary or conventional intervention is effective for treating or preventing alcohol hangover, say researchers in this week's BMJ.

In Britain, alcohol hangovers account for about £2bn in lost wages each year, mostly due to sickness absence, and a plethora of "hangover cures" is on offer.

The team searched medical databases and the internet, and contacted experts and manufacturers for randomised controlled trials of any medical intervention for preventing or treating alcohol hangover.

They found eight trials testing eight different agents: propranolol (beta-blocking drug), tropisetron (drug for nausea and vertigo), tolfenamic acid (painkiller), fructose or glucose, and the dietary supplements borage, artichoke, prickly pear, and a yeast based preparation.

Most trials reported no beneficial effects, although encouraging findings existed for borage, a yeast based preparation, and tolfenamic acid.

"We are confident that our search strategy located all published trials on the subject," say the authors. "Our findings show no compelling evidence to suggest that any complementary or conventional intervention is effective for treating or preventing the alcohol hangover."

The most effective way to avoid the symptoms of alcohol induced hangover is thus to practise abstinence or moderation, they conclude.
-end-


BMJ

Related Drug Articles from Brightsurf:

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance.

Potent drug supply drop, not domestic drug policies, likely behind 2018 OD death downturn
The slight decline in drug overdose deaths in 2018 coincides with Chinese regulations on the powerful opioid carfentanil, rather than the result of domestic U.S. efforts to curb the epidemic, a new analysis reveals.

Old drug standards delay new drug approvals
The more information the FDA has about existing drugs, the longer it takes to OK new ones for the same conditions.

What drug companies spend to bring a new drug to market
Researchers estimated the cost to bring 63 new drugs or biologics to market between 2009 and 2018 using publicly available data on research and development expenditures for these medicines.

New flu drug drives drug resistance in influenza viruses
University of Wisconsin-Madison researchers examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

Cause of drug resistance in a drug resistance in intestinal tumors identified
Researchers clarify mechanisms that allow hard-to-treat cancers to develop, and have identified strategies that could lead to new therapies.

AI could offer warnings about serious side effects of drug-drug interactions
Researchers at Penn State have developed a machine learning system that may be able to warn doctors and patients about possible negative side effects that might occur when drugs are mixed.

Charcoal-based drug delivery system improves efficacy of common herpes drug
A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir -- a commonly prescribed topical herpes medication -- with particles of activated carbon improves efficacy of the drug.

Candida auris is a new drug-resistant fungus emerging globally and in the US early detection is key to controlling spread of deadly drug-resistant fungus
Early identification of Candida auris, a potentially deadly fungus that causes bloodstream and intra-abdominal infections, is the key to controlling its spread.

Arming drug hunters, chemists design new reaction for drug discovery
Colorado State University organic chemists have forged a powerful new tool for drug hunters -- a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.

Read More: Drug News and Drug Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.